ArticleInternational journal of legal medicine2026
Molecular forensics: RNA degradation as a marker for postmortem interval determination.
Article in International journal of legal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Determining the time since death (TSD) is crucial in forensic investigations, yet it remains a complex process influenced by numerous postmortem factors. This study explores RNA degradation as a promising marker for precise TSD estimation, leveraging real-time quantitative polymerase chain reaction to quantify degradation rates. We analysed degradation patterns of messenger RNA (mRNA), ribosomal RNA (rRNA), and microRNA (miRNA) across liver, lung, and heart tissues, focusing on housekeeping genes (GAPDH, ACTB, RPS10, RPS29) and rRNA (5 S, 18 S, 28 S), alongside tissue-specific miRNAs (miR-122, miR-195, miR-200c, miR-1, U6). RNA yield, and purity varied significantly among tissues, with the liver showing higher RNA yields but lower purity compared to the heart and lung. RPS29 and RPS18 emerged as stable reference markers, unlike GAPDH and ACTB, which showed postmortem instability. rRNA demonstrated greater resilience to degradation compared to mRNA, with distinct patterns peaking at 60-84 h postmortem. miRNAs, particularly miR-122, and miR-1, showed potential as TSD biomarkers due to their relative stability. A mathematical model for TSD estimation was developed using 14,400 Ct values from 600 tissues analyzed in R-studio. The model demonstrated high to moderate predictive accuracy across three tissues under controlled environmental conditions. The model achieved the highest accuracy in heart (R² = 0.75), followed by liver (R² = 0.739), with the lowest predictive power observed in lung (R² = 0.57). These findings underscore the effectiveness of RNA degradation profiles, particularly rRNA and microRNAs, in TSD estimation and highlight the importance of integrating multiple tissues and tissue-specific markers for enhanced forensic reliability.
Indexed as
Identifiers
41507519What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.